刘建文 教授 博士生导师
--------------------------------------------------------------------------------
电话: 021-64252044 ;021-64252262
--------------------------------------------------------------------------------
传真: 021-64252044
--------------------------------------------------------------------------------
E-mail: liujian@ecust.edu.cn
--------------------------------------------------------------------------------
个人简介
--------------------------------------------------------------------------------
刘建文，1994年毕业于上海中医药大学获得医学博士学位；1995年应日本国科学技术厅邀请，作为STA Fellow在大阪生物科学研究所(Osaka Bioscience Institute)和日本理化学研究所(Institute of Physical and Chemical Research)进行客座研究。研究天然药物对血管内皮细胞纤溶活性因子的基因调空作用。2001年毕业于日本广岛大学(省立)遗传子制御工学研究室，研究自由基与癌转移的过程及实验药物干预的分子机理，获得应用生物科学博士学位。现主要研究方向：细胞周期阻滞及凋亡诱导剂的发现与作用机理研究；肿瘤细胞凋亡小分子RNA表达、调控的研究及其在新药研发中的应用；基于肿瘤光动力的分子模型的建立及先导化合物的发现研究。通过整体动物水平，离体细胞和分子水平研究新物质的药理药效学作用和机理，研究新物质对靶细胞作用后的蛋白水平，基因水平的影响，建立了以肿瘤学为主的分子细胞药理学研究特色。曾在国际肿瘤治疗学领域发现了通过抑制肿瘤细胞内的ROS(Reactive Oxygen Species)，可以达到抑制癌细胞浸润转移的目的，该研究为开发非杀伤性抗癌转移的药物提出新的科学依据。论文被学术界引用和国际学术会议交流。主持国家和省部级科研课题。参与获得省部级科研成果一等奖2项、二等奖6项，三等奖3项申请发明专利11项，国际发明专利1项，发表国内外论文近140篇，其中SCI收录82篇。主编《药理实验方法学—新技术与新方法》，《生物资源中活性物质的开发与利用》，参编《血管内皮细胞与疾病》，《生物抗氧化剂》（日文）。
--------------------------------------------------------------------------------
现主要研究领域：
分子、细胞生物学，医学肿瘤学，药理、毒理学，中药学
现主要研究方向：
1，细胞周期阻滞及凋亡诱导剂的发现与作用机理研究
2，肿瘤细胞凋亡下分子RNA表达、调控的研究及其在新药研发中的应用
3. 基于肿瘤光动力的分子模型的建立及先导化合物的发现研究
4，生物抗氧化剂的应用基础研究
5. 纳米材料与技术在生命科学中的应用基础研究
获奖成果
-------
湖北省科研成果（1992年）三等奖
2006年度高等学校科学技术奖自然科学二等奖
2006年度上海市科技进步二等奖
2007年度上海医学科技奖三等奖
2007年度中华中医药学会科学技术奖三等奖
2013年度高等学校科学技术进步奖二等奖
2013年度上海市科技进步一等奖
2014年度高等学校科学研究 自然科学奖一等奖
2014年度高等学校科学研究 科技进步奖二等奖
2014年度中华医学科技奖 二等奖
2016上海中西医结合科学技术奖二等奖
主要出版编著
--------------------------------------------------------------------------------
1. 盛民立，刘建文 等: 《血管内皮细胞与疾病》 上海医科大学出版社（上海，1993, 12.）ISBN 7－5627－0176－8/R.167
2. 三羽信比古，刘建文 等: 《生物抗氧化剂》日本Fragrance杂志社 1999, 9, 30.（日文）ISBN 4－89479－017－3
3. 刘建文 主编 《药理实验方法学—新技术与新方法》化学工业出版社生物医药出版中心（北京，2003.5）ISBN 7－5025－3271－4
4. 三羽信比古，刘建文 等: 《美肤，皮肤防护与生物技术》日本CMC杂志社 2003.7（日文）ISBN 4－88231－408－8
5.刘建文，贾伟主编《生物资源中活性物质的开发与利用》化学工业出版社（北京，2005.5）ISBN 7－5025－7133－7
6. 李仪奎主编，刘建文 参编 《中药药理实验方法学》 上海科学技术出版社 (上海，2006.5）
7.刘建文 主编 《药理实验方法学—新技术与新方法》化学工业出版社生物医药出版中心（北京，2008.1第二版）ISBN 978-7-112-01064-3/R.965.2
8.刘建文主编 《药理学》十一五国家重点图书，普通高等教育制药类专业规划教材，华东理工大学出版社（上海，2010.4）ISBN 978－7－5628－2753-5/R.18
9. 陈奇主编，刘建文参编 《中药药理研究方法学》 人民卫生出版社 （北京2011.12）ISBN 978－7－117－14398-1/R.14399
10.陈奇，张伯礼主编，刘建文参编《中药药效研究方法学》人民卫生出版社（北京2016.5）ISBN 978－7－117－22052-1/R.22053
主要发表论文
1. Wen Xu, Jianwen Liu*, Changlong Li, He-Zhen Wu, Yan-Wen Liu: Kaempferol-7-O-β-D-glucoside (KG) isolated from Smilax china L. rhizome induces G2/M phase arrest and apoptosis on HeLa cells in a p53-independent manner. Cancer Letters 2008,264: 229–240.
2. Jin Wang, Aibin Wu, Yufang Xu, Jianwen Liu*, Xuhong Qian* M2-A, a novel amonafide analogue, induces apoptosis and G2-M arrest via inhibiting PI3K/Akt pathway on HL60 cells. Cancer Letters 2009,283:193–202.
3. Mingcang Chen, Yiyi Ye, Jianwen Liu,* Guang Ji Hesperidin Upregulates Heme Oxygenase-1 To Attenuate Hydrogen Peroxide-Induced Cell Damage in Hepatic L02 Cells. J. Agric. Food Chem 2010, 58:3330–3335.
4. Xin Liang, Yufang Xu, Ke Xu, Jianwen Liu*, and Xuhong Qian. B1, a Novel Amonafide Analogue, Overcomes the Resistance Conferred by Bcl-2 in Human Promyelocytic Leukemia HL60 Cells. Mol Cancer Res, 2010, 8:1619-1632.
5. Xin Liang, Aibin Wu, Yufang Xu, Ke Xu, Jianwen Liu*, Xuhong Qian* :B1, a novel naphthalimide-based visible light activatable photonuclease, induces cell cycle arrest and apoptosis via Chk2-p53 pathway in HeLa cells. Invest New Drugs 2011, 29, (4): 646-658.
6. Xin Liang , Ke Xu, Yufang Xu, Jianwen Liu* , Xuhong Qian: B1-induced caspase-independent apoptosis in MCF-7 cells is mediated by down-regulation of Bcl-2 via p53 binding to P2 promoter TATA box. Toxicol Appl Pharm 2011,256 : 52–61.
7. Ke Shen, Qiannan Liang, Ke Xu, Daling Cui, Lin Jiang, Peihao Yin, Yanhua Lu, Qi Li, Jianwen Liu*: MiR-139 inhibits invasion and metastasis of colorectal cancer by targeting the type I insulin-like growth factor receptor. Biochem Pharmacol 2012,84:320–330.
8. Ke Xu, Xin Liang, Ke Shen, Daling Cui, Yuanhong Zheng,Jianhua Xu, Zhongze Fan, Yanyan Qiu, Qi Li, Lei Ni, Jianwen Liu*: MiR-297 modulate multidrug resistance in human colorectal carcinoma by down-regulating MRP-2. Biochem J 2012, 446(2): 291-300.
9. Ke Xu, Xin Liang, Ke Shen, Liyun Sun, Daling Cui, Yuxia Zhao, Jianhui Tian, Lei Ni, Jianwen Liu*: MiR-222modulatesmultidrug resistance in human colorectal carcinoma by down-regulating ADAM-17. Exp Cell Res 2012, 318: 2168–2177.
10. Ke Xu, Xin Liang, Daling Cui, Yixin Wu, Weibin Shi and Jianwen Liu*: miR-1915 Inhibits Bcl-2 to Modulate Multidrug Resistance by Increasing Drug-Sensitivity in Human Colorectal Carcinoma Cells. Mol Carcinogen 2013, 52:70–78 .
11. Ke Shen, Liyun Sun, Huanying Zhang, Yufang Xu, Xuhong Qian, Yanhua Lu, Qi Li, Lei Ni, Jianwen Liu*:A ROS-mediated lysosomal–mitochondrial pathway is induced by a novel Amonafide analogue, 7c, in human Hela cervix carcinoma cells. Cancer Letters 2013,333: 229–238.
12. Ke Shen, Li Ma, Yi Li, Yanyan Qiu, Daling Cui, Yanhua Lu, Peihao Yin, Jianwen Liu*: A Post-Transcriptional Regulation of Tumor Suppressor MiR-139-5p and A Network of MiR-139-5p Mediated mRNAs Interactions in Colorectal Cancer. FEBS Journal 2014, 281: 3609–3624.
13. Yichun Xu, Shuai Han, Xinhua Huang, Shichao Zhuo, Huiqing Dai, Ke Wang, Zhou Li, Jianwen Liu*. An effective method based on real time fluorescence quenching for Single nucleotide polymorphism detection. Journal of Biotechnology 2014,186:156–161.
14. Van-Minh Le, Jing-Jing Wang, Ming Yuan, The-Long Nguyen, Gui-Fang Ying, Yuan-Hong Zheng, Wei-Bin Shi, Mei-Dong Lang, Lei-Ming Xu, Jianwen Liu*: An investigation of antitumor efficiency of novel sustained and targeted 5-fluorouracil Nanoparticles. European Journal of Medicinal Chemistry 2015,92: 882-889.
15. Yuanhong Zheng, Fangyuan Zou, Jingjing Wang, Guifang Yin, Vanminh Le, Zhewei Fei, and Jianwen Liu*: Photodynamic Therapy-mediated Cancer Vaccination Enhances Stem-like Phenotype and Immune Escape, Which Can Be Blocked by Thrombospondin-1 Signaling through CD47 Receptor Protein. J Biol Chem. 2015, 290, 8975-8986.
16，Rurong Mao, Fangyuan Zou, Liyan Yang, Shengchao Lin, Yueqi Li, Mingxing Ma, Peihao Yin, Xin Liang, Jianwen Liu*: The Loss of MiR-139-5p Promotes Colitis-Associated Tumorigenesis by Mediating PI3K/AKT/Wnt Signaling Int J Biochem Cell B 2015, 69:153–161.
17, Shengchao Lin, Kecheng Lei, Wenpei Du, Liyan Yang, Haiyang Shi, Yuwei Gao,
Peihao Yin, Xin Liang, Jianwen Liu*: Enhancement of oxaliplatin sensitivity in human colorectal cancer by hypericin mediated photodynamic therapy via ROS-related mechanism. Int J Biochem Cell B 2016,71: 24–34.
18. Yuanhong Zheng, Guifang Yin, Vanminh Le, Anle Zhang, Peihao Yin, Jianwen Liu*, Photodynamic-therapy Activates Immune Response by disrupting Immunity Homeostasis of Tumor Cells, Which Generates Vaccine for Cancer Therapy Int J Biol Sci 2016; 12(1): 120-132.
19, Fangyuan Zou, Rurong Mao, Kecheng Lei, Liyan Yang, Yue Ding, Peng Zhang, Jiyu Li, Xin Liang*, Jianwen Liu*: Targeted Deletion of miR-139-5p Enhances Colon Inflammation and Tumorigenesis through Negatively Regulating MAPK, NF-κB, and STAT3 Signaling PathwaysFEBS Journal, 2016, 283:1438-1452.
20.Jie Li, Kecheng Lei, Zengrui Wu, Weihua Li, Guixia Liu, Jianwen Liu*, Feixiong Cheng, Yun Tang: Network-based identification of microRNAs as potential pharmacogenomic biomarkers for anticancer drugs. Oncotarget2016,7(29): 45584-45596.
21. Lin Zhou, Xin Liang2, Lingling Zhang, Liyan Yang, Norio Nagao, Hongkun Wu, Chang Liu, Shengchao Lin, Guoxiang Cai, Jianwen Liu*: MiR-27a-3p functions as an oncogene in gastric cancer by targeting BTG2. Oncotarget 2016, 32(7): 51943-51954.
22. Ke Xu, Ke Shen, Xin Liang, Yueqi Li, Norio Nagao, Jiyu Li, Jianwen Liu*, Peihao Yin: MiR-139-5p reverses CD44+/CD133+-associated multidrug resistance by downregulating NOTCH1 in colorectal carcinoma cells Oncotarget, 2016,7(46): 75118-75129.
23，Xin Liang, Haiyang Shi, Liyan Yang, Cen Qiu, Shengchao Lin, Yingxue Qi, Jiyu Li, Aiguang Zhao, and Jianwen Liu*: Inhibition of polypyrimidine tract-binding protein 3 induces apoptosis and cell cycle arrest, and enhances the cytotoxicity of 5- fluorouracil in gastric cancer cells. Br J Cancer. 2017,116(7):903-911.
24，Lei K, Liang X, Gao Y , Xu B, Xu Y , Li Y , Tao Y , Shi W, Liu J*. Lnc-ATB Contributes to Gastric Cancer Growth Through a MiR-141-3p/TGFβ2 Feed back Loop. Biochemical and Biophysical Research Communications 2017;484(3): 514-521.